Theory and Applications of Covalent Docking in Drug Discovery: Merits and Pitfalls
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
he present art of drug discovery and design of new drugs is based on suicidal irreversible inhibitors. Covalent inhibition is the strategy that is used to achieve irreversible inhibition. Irreversible inhibitors interact with their targets in a time-dependent fashion, and the reaction proceeds to completion rather than to equilibrium. Covalent inhibitors possessed some significant advantages over non-covalent inhibitors such as covalent warheads can target rare, non-conserved residue of a particular target protein and thus led to development of highly selective inhibitors, covalent inhibitors can be effective in targeting proteins with shallow binding cleavage which will led to development of novel inhibitors with increased potency than non-covalent inhibitors. Several computational approaches have been developed to simulate covalent interactions; however, this is still a challenging area to explore. Covalent molecular docking has been recently implemented in the computer-aided drug design workflows to describe covalent interactions between inhibitors and biological targets. In this review we highlight: (i) covalent interactions in biomolecular systems; (ii) the mathematical framework of covalent molecular docking; (iii) implementation of covalent docking protocol in drug design workflows; (iv) applications covalent docking: case studies and (v) shortcomings and future perspectives of covalent docking. To the best of our knowledge; this review is the first account that highlights different aspects of covalent docking with its merits and pitfalls. We believe that the method and applications highlighted in this study will help future efforts towards the design of irreversible inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Examples of covalent inhibitors including their protein target(s) with active-site nucleophile: (A) aspirin; (B) neratinib; (C) rivastigmine; (D) Crystal structure of EGFR kinase domain in complex with neratinib, showing the covalent bond between the receptor and the ligand [27].](https://figures.cochat.ai/paper-figures/4c29b35814fb4c5895f870ace31f2ee7/theory-and-applications-of-covalent-docking-in-drug-discovery-merits-and-figure-1.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Due to the increasing interest in covalent drugs, many non-covalent docking programs have developed covalent versions and some new docking programs focused on covalent ligands have been developed (Kumalo et al., 2015; Awoonor-Williams et al., 2017; De Cesco et al., 2017).”
From Empirical scoring functions for structure-based virtual screening: applications, critical aspects, and challenges (2018) · cites this paper as Kumalo et al., 2015
In the citing paper
“However, the majority of covalent algorithms are limited to accurately calculating the binding energy between a nucleophilic protein and an electrophilic small molecule (Fig. 4) [74].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [74]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412 · cited 1×
“The most common docking programs and software include Autodock [31], Autodock Vina [32], GOLD [33] and FlexX [34].”
MethodAutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21256 · Cited by 25,486 · cited 5×
“The most common docking programs and software include Autodock [31], Autodock Vina [32], GOLD [33] and FlexX [34].”
BackgroundMethodInfluentialFriesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C., & Mainz, D. T. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051256o · Cited by 6,851 · cited 1×
“com/web/ Autodock [60] Glide [61] CovDock [62]”
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763 · cited 4×
“Zhang et al., reported covalent docking (using GOLD version 4.0) in conjunction with molecular dynamics (MD) simulation (Amber Molecular Dynamics Package version 8.0) to explore the binding mode of peptide aldehyde inhibitors as anti-tumor drugs (Figure 4C,D).”
MethodInfluentialA Fast Flexible Docking Method using an Incremental Construction Algorithm
Rarey, M., Kramer, B., Lengauer, T., & Klebe, G. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0477 · Cited by 2,827 · cited 2×
“The most common docking programs and software include Autodock [31], Autodock Vina [32], GOLD [33] and FlexX [34].”
BackgroundMethodThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 1×
“Examples of covalent inhibitors including their protein target(s) with active-site nucleophile: (A) aspirin; (B) neratinib; (C) rivastigmine; (D) Crystal structure of EGFR kinase domain in complex with neratinib, showing the covalent bond between the receptor and the ligand [27].”
BackgroundThe resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873 · cited 3×
“However, not all drugs bind non-covalently to the active site; there are other categories of drugs, namely the covalent drugs [14].”
BackgroundInfluentialAcetylation of prostaglandin synthase by aspirin.
Roth, G. J., Stanford, N., & Majerus, P. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.8.3073 · Cited by 1,009 · cited 1×
“The earliest example of a covalent drug is aspirin, which was first marketed over a century ago; aspirin covalently modifies cyclooxygenase by inducing the acetylation of a serine residue that is situated in the active site (Figure 1A) [15–18].”
BackgroundAbagyan, R., & Totrov, M. (1994) · Journal of Molecular Biology · doi:10.1006/jmbi.1994.1052 · Cited by 975 · cited 1×
“Abagyan and Totrov developed a 4D-docking protocol for Internal Coordinate Mechanics (ICM), where the receptor conformation is the fourth dimension [63–65].”
MethodDrugging Topoisomerases: Lessons and Challenges
Pommier, Y. (2013) · ACS Chemical Biology · doi:10.1021/cb300648v · Cited by 839 · cited 1×
“These types of inhibitors derive their activity from both non-covalent interactions and the formation of the covalent bond between the inhibitor and the target protein [8–13].”
Background
Research works printed but not linked: 1
- Ding, 2002, Computational manufacturing, Prog. Nat. Sci., 12, 641
Cited by
Items 101–162 of 162
Bourdon, A. K., Villareal, G., Perry, G. L., & Phelix, C. F. (2017) · International Journal of Knowledge Discovery in Bioinformatics · doi:10.4018/ijkdb.2017070104 · Cited by 4
Rational design of new leishmanicidal agents: In silico and In vitro evaluation.
Andrade Ochoa, S. (2015) · Figshare · doi:10.6084/m9.figshare.1619665 · Cited by 5
Shafiu, S., Edache, E. I., Sani, U., & Abatyough, M. (2017) · Journal of Pharmaceutical and Medicinal Research · Cited by 4
Yang, Q., Yao, L., Jia, F., Pang, G., Huang, M., Liu, C., Luo, H., & Fan, L. (2024) · Chemometrics and Intelligent Laboratory Systems · doi:10.1016/j.chemolab.2024.105271 · Cited by 3
Chhikara, B. S., Kumar, R., Singh, J., & Kumar, S. (2024) · Biomedical and Therapeutics Letters · doi:10.62110/sciencein.btl.2024.v11.920 · Cited by 10
Kumi, R. O., Issahaku, A. R., Soremekun, O. S., Agoni, C., Olotu, F. A., & Soliman, M. E. S. (2019) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207322666190927143026 · Cited by 3
Self-citationOlawale, F., Ogunyemi, O. M., & Folorunso, I. M. (2022) · Molecular Simulation · doi:10.1080/08927022.2022.2101673 · Cited by 3
Tiwari, M., Gupta, S., & Bhargava, P. (2022) · Journal of Applied and Natural Science · doi:10.31018/jans.v14i4.3641 · Cited by 3
“Molecular docking is a widely used technique to help researchers to predict the arrangement of small molecules within the 3D structure of the receptor along with the affinity of the ligand to the target with appreciable accuracy and efficacy (Kroemer, 2007 and Kumalo et al., 2015).”
Method(2023) · Biointerface Research in Applied Chemistry · doi:10.33263/briac135.460 · Cited by 4
What Do Reactive Fragments Actually Do in Cells?
Plettenburg, O. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201607914 · Cited by 3
Afriza, D., Suriyah, W. H., Ichwan, S. J. A., & Knights, J. (2024) · Padjadjaran Journal of Dentistry · doi:10.24198/pjd.vol36no1.52467 · Cited by 2
Molecular Docking: A Computational Approach Streamlining Drug Design
Sundaram, B., & Ahmed, S. (2025) · IGI Global eBooks · doi:10.4018/979-8-3693-5598-5.ch013 · Cited by 3
Machida, T., Gong, Y., Tsukioka, S., Onodera, A., Nakayama, A., Hashimoto, N., Fuchigami, T., Nishimura, M., Ogino, T., Kurimoto, R., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70984-1 · Cited by 2
“Covalent inhibitors, such as ORY-1001 and GSK2879552, irreversibly modify the FAD cofactor to block catalysis 14 ; however, irreversible binding raises concerns about off ‑ target effects, limited adaptability for rapidly turning ‑ over enzymes, and potential immunogenicity 4,13,15 .”
Hudson, I. L., Leemaqz, S., Neffe, A. T., & Abell, A. D. (2016) · Studies in computational intelligence · doi:10.1007/978-3-319-28495-8_9 · Cited by 3
Du, L., Suo, S., Zhang, H., Jia, H., Liu, K. J., Zhang, X. J., & Liu, Y. (2016) · Nanotechnology · doi:10.1088/0957-4484/27/44/445101 · Cited by 2
Drug Discovery: Current State and Future Prospects
Prabu, S. L. (2018) · Advances in medical technologies and clinical practice book series · doi:10.4018/978-1-5225-7326-5.ch001 · Cited by 4
Kumar, S., Choudhary, N., Faruq, M., Kumar, A., Saran, R. K., Indercanti, P. K., Singh, V., Sait, H., Jaitley, S., Vališ, M., et al. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2176927 · Cited by 2
“…has been a growing interest in the design of drugs involved in covalent interactions for their stronger binding affinities with target molecules (Kumalo et al., 2015); a high inhibitory action of anastrozole against ANT is suggested by its involvement in both covalent and non-covalent…”
BackgroundPDB ‐ CAT : A user‐friendly tool to classify and analyze PDB protein–ligand complexes
Llop‐Peiró, A., León, S. T., Pujadas, G., Garcı́a-Vallvé, S., & Gimeno, A. (2025) · Protein Science · doi:10.1002/pro.70379 · Cited by 1
Leng, J., Huang, Z., Zheng, L., Yang, Y., Huang, H., Gao, Y., Huo, L., Li, Y., Sun, Z., & Zhang, J. Z. H. (2026) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp04981d · Cited by 1
Piperine inhibits NLRP3 inflammasome activation and alleviates inflammatory disease
Guo, R., Niu, Z., Chen, F., Zheng, L., Li, J., Qi, L., Wu, G., Wang, X., Xu, F., Cho, J. Y., et al. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158448 · Cited by 1
In Silico Insights Toward the Exploration of Adenosine Receptors Ligand Recognition
Bassani, D., & Moro, S. (2023) · Topics in medicinal chemistry · doi:10.1007/7355_2023_164 · Cited by 1
Gerges, A., & Canning, U. (2025) · Exploration of Drug Science · doi:10.37349/eds.2025.1008109 · Cited by 1
High-Risk Neuroblastoma Stage 4 (NBS4): Developing a Medicinal Chemistry Multi-Target Drug Approach
Gerges, A., & Canning, U. (2025) · Molecules · doi:10.3390/molecules30102211 · Cited by 1
“Computational methods such as molecular docking, homology modelling, molecular dynamics, and quantitative structure–activity relationships (QSAR) are frequently used as part of the process for finding new therapeutic drug targets using computational methods [12].”
Computational identification of potential COX-2 inhibitors from Devil’s Claw for anti-inflammation
Martin, D. R., Oselusi, S. O., Armien, A., Sibuyi, N. R. S., Meyer, M., & Madiehe, A. M. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100370 · Cited by 1
Advances in Docking-Based Drug Design for Microbial and Cancer Drug Targets
Gupta, D., & Khan, A. U. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822312-3.00020-5 · Cited by 1
In silico Study of the Interactions between Schiff Base Polyphenols and HPV 16 E6/E6AP/p53 complex
Ogah, J. I., Kolawole, O. M., Oguntoye, S. O., & Suleiman, M. M. (2021) · Nigerian Journal of Pure and Applied Sciences · doi:10.48198/njpas/21.a19 · Cited by 1
Docking Methodologies and Recent Advances
Kumar, A., Goyal, R., & Jain, S. (2016) · IGI Global eBooks · doi:10.4018/978-1-5225-0549-5.ch031 · Cited by 1
Veljović, E., Harej, A., Klobučar, M., Pavelić, S. K., Špirtović‐Halilović, S., Osmanović, A., Muratović, S., Salihović, M., & Završnik, D. (2022) · Kemija u industriji · doi:10.15255/kui.2021.030 · Cited by 1
Putilina, M. V. (2024) · Terapevticheskii arkhiv · doi:10.26442/00403660.2024.02.202583 · Cited by 1
Covalent Flexible Peptide Docking in Drug Discovery: Current Challenges and Potential Interventions
Lafifi, Z., Bjij, I., & Soliman, M. E. S. (2024) · Innovation Discovery · doi:10.53964/id.2024015 · Cited by 1
Self-citationAdeniji, E. A., Olotu, F. A., Shunmugam, L., & Soliman, M. E. S. (2019) · Molecular Simulation · doi:10.1080/08927022.2019.1578355 · Cited by 1
Self-citationThe Comparison of Docking Search Algorithms and Scoring Functions: An Overview and Case Studies
Novič, M., Tibaut, T., Anderluh, M., Borišek, J., & Tomašič, T. (2016) · IGI Global eBooks · doi:10.4018/978-1-5225-1762-7.ch032 · Cited by 3
An overview of Quinazolines: Applicability of molecular docking in Cancer therapy
Yadav, M. K., Prasad, T., Rathi, R., Kushwaha, V. K., Kumar, V., Yadav, S., Kumar, D., & Rai, S. (2023) · International Journal of Pharma Professional’s Research (IJPPR) · doi:10.48165/ijppronline.2023.14204 · Cited by 1
Prospects of Covalent Approaches in Drug Discovery: An Overview
Ramachandran, B., Saravanan, M., & Jeyakanthan, J. (2021) · Wiley eBooks · doi:10.1002/9781119654803.ch15 · Cited by 1
Docking Methodologies and Recent Advances
Kumar, A., Goyal, R., & Jain, S. (2016) · Advances in medical technologies and clinical practice book series · doi:10.4018/978-1-5225-0115-2.ch012
Covalent Kinase Inhibitors for Cancer
Owens, T. D., & Lou, Y. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12399-6 · Cited by 1
Was genau machen reaktive Fragmente eigentlich in Zellen?
Plettenburg, O. (2016) · Angewandte Chemie · doi:10.1002/ange.201607914
Antiproliferative Evaluation and Docking Study of Synthesized Biscoumarin Derivatives
Muratović, S., Veljović, E., Osmanović, A., Djedjibegovíc, J., Nikšić, H., Džudžević-Čančar, H., & Završnik, D. (2017) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-981-10-4166-2_112
Modeling Covalent Protein-Ligand Interactions
Ward, R. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11519-3
Squaric ester applications as novel lysine electrophiles in molecular probe design
Ho, J. S. (2020) · DSpace@MIT (Massachusetts Institute of Technology)
The activity of nybomycin against mycobacterium tuberculosis.
Niehaus, A. J. (2018) · ResearchSpace (University of KwaZulu-Natal)
Phelix, C. F., Bourdon, A. K., Dugan, J. L., Villareal, G., & Perry, G. L. (2020) · IGI Global eBooks · doi:10.4018/978-1-7998-3441-0.ch022
Bourdon, A. K., Villareal, G., Perry, G. L., & Phelix, C. F. (2020) · IGI Global eBooks · doi:10.4018/978-1-7998-3441-0.ch021
Khelfaoui, H., Harkati, D., Saleh, B. A., Hewitt, N. L., Alnajjar, R. A., & El-Hiti, G. A.-R. (2023) · Polycyclic aromatic compounds · doi:10.1080/10406638.2023.2237628 · Cited by 1
“EGFR kinase activating mutations occur in exons 18 – 21 and are classified into three categories, the deletion of exon-19, the substitution of a single nucleotide that changes the coded amino acid, and in-frame duplication and insertion of exon 20.”
BackgroundMolecular recognition of anion binding proteins: Characterization and inhibition
Schuurs, Z. P. (2023) · Queensland University of Technology · doi:10.5204/thesis.eprints.246091
Aljoundi, A. (2021) · ResearchSpace (University of KwaZulu-Natal) · doi:10.29086/10413/22663
Genetic Variation Affects the Anti-Melanogenic Efficacy of Platycodon grandiflorus Flowers
Kim, E., & Hyun, T. K. (2024) · Applied Sciences · doi:10.3390/app14166867
“The molecular docking approach is a pivotal tool in analyzing the interactions between target proteins and small molecules, greatly contributing to the discovery of high-quality enzyme inhibitors that have progressed to clinical trials [36].”
BackgroundCovalent Inhibitors of MAP Kinases
De, S. K. (2024) · Springer eBooks · doi:10.1007/978-3-031-75682-5_5
Agu, G. C., Sossou, I. T., Abiola, T., Afolabi, O. T., Sanusi, A. S., & Atunnise, A. (2024) · Nigerian Journal of Biochemistry and Molecular Biology · doi:10.4314/njbmb.v39i3.9
Theoretical investigation of covalent inhibitors targeting ricin
Botelho, F. D., Magalhães, M. N., Ajamian, A., dos Santos, M. C., LaPlante, S. R., & França, T. C. C. (2025) · New Journal of Chemistry · doi:10.1039/d5nj01464f
Martinez-Martinez, R. E., Calva-Hernandez, C. I., Rodríguez-López, G. M., Soria-Castro, R., Ruiz‐Sánchez, B. P., Chávez-Blanco, A. D., Pérez‐Tapia, S. M., Pavano-Rodriguez, C. G., & Chacón‐Salinas, R. (2025) · Cureus · doi:10.7759/cureus.90680
“VPA (144 g/mol) is considerably lower with respect to ibrutinib (440.5 g/mol) and FCPA (510 g/mol); in addition, the atomic interactions between BTK and VPA are considered weak [28].”
InfluentialZhu, J., Qiu, G., Xu, L., Cai, Y., Chen, Y., & Jin, J. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11329-w
“…application of a covalent docking feature necessitates the manual specification of reactive atoms and the type of reaction, or the docking program may be limited in the variety of covalent reaction types available, both of which create challenges in scaling the process for screening purposes [24].”
Covalent Docking to the Active Sites of Thiamine Diphosphate-Dependent Enzymes
Artiukhov, A. V., & Aleshin, V. A. (2025) · Molecules · doi:10.3390/molecules30224427 · Cited by 1
“However, recent drug design studies have found that as much as one third of FDA-approved drugs may act via covalent binding to the desired or undesired targets [32,33].”
Putra, S. S. S., Alias, Y. B., Basirun, W. J., Ibrahim, M., Elgharbawy, A. A. M., Tola, H., Hayyan, A., & Hashim, M. A. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.150172
Development of small molecules modulating the activity of the nucleoside kinase dCK
Yaala, K. B. (2021) · theses.fr (ABES) · doi:10.70675/749d80bcze0abz4780za87czd786c1617d69
Predicting unknown binding sites for transition-metal-based compounds in proteins
Levy, A., & Röthlisberger, U. (2026) · PLoS ONE · doi:10.1371/journal.pone.0349622
Introduction to Computational Models in Drug Interaction Prediction
Sharma, N., Anurag, B. S. P., Siddiqui, N., Saifi, A., Chawla, R. L., & Sharma, A. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814328126010011
Towards an enzyme cascade synthesis of the bulk chemical acrylic acid
Zhao, H., Wang, C., Zhang, S., Wang, Q., Chu, H., Yang, J., Zhang, L., Xu, Z., Zhuo, B., Liu, C., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-75484-w
“14).”
High‐Throughput Technologies for Targeted Covalent Drug Discovery: Recent Advances and Perspectives
Yu, H., Wang, X., Wang, X., & Yin, Y. (2026) · Chemistry - A European Journal · doi:10.1002/chem.71680
BindingDB (2026) · UC San Diego · doi:10.7270/q22n575t
BindingDB Entry 50015871: Advanced approaches of developing targeted covalent drugs.
BindingDB (2023) · UC San Diego · doi:10.7270/q2df6w53
BindingDB Entry 50000850: Discovery of highly potent, selective, covalent inhibitors of JAK3.
BindingDB (2020) · UC San Diego · doi:10.7270/q2x069hq
Metadata
- Authors
- Kumalo, H., Bhakat, S., & Soliman, M.
- Affiliations
- University of KwaZulu-Natal (ZA)
- Corresponding author
- Soliman, Mahmoud
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2015-01-27
- Volume
- 20
- Issue
- 2
- Pages
- 1984-2000
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC6272664
- OpenAlex
- W2029963983
- Cited by
- 158
- References
- 68
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 10 · 2023: 17 · 2022: 11 · 2021: 17 · 2020: 17 · 2019: 11 · 2018: 13 · 2017: 13 · 2016: 19 · 2015: 5
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Research Foundation
- Inyuvesi Yakwazulu-Natali
- Center for High Performance Computing
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- covalent docking, covalent inhibitors, irreversible inhibition, computer-aided drug design, covalent interactions, protein-ligand binding, covalent warheads, selective inhibitors
- MeSH terms
- Humans, Protein Binding, Software, Thermodynamics, Drug Discovery, Molecular Docking Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.